Predictive Value of Tumor-Infiltrating Lymphocytes for Neoadjuvant Chemotherapy Among Triple-Negative Breast Cancer

Authors

  • Yuan Xu School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, China

DOI:

https://doi.org/10.54097/j931ky70

Keywords:

Tumor-infiltrating lymphocytes; triple-negative breast cancer; neoadjuvant chemotherapy.

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with high recurrence risk. Currently, neoadjuvant chemotherapy (NAC) serves as the core therapeutic option for TNBC, which requires effective biomarkers to predict patient prognosis. As the key component of the tumor immune microenvironment (TIME) in the tumor microenvironment (TME), Tumor-infiltrating lymphocytes (TILs) have been confirmed to be correlated with NAC prognosis of TNBC by existing studies, yet most of these studies focus only on patients with early-stage TNBC. In addition, no unified interpretation standard has been established. This review reveals the cellular composition of TILs and the anti-tumor immune mechanisms of TILs subsets, summarizes the internationally quantitative evaluation criteria and published clinical research findings and confirms that stromal tumor-infiltrating lymphocytes (sTILs) can facilitate the prediction of the patients prognosis receiving NAC. This review provides a theoretical support for the application of TILs in the precise stratified treatment of TNBC and the efficacy evaluation of new drugs. At present, in-depth research is still needed to clarify the immune pathway mechanisms of each TIL subset, improve stage-specific research, and standardize the interpretation and assessment of TILs. In future research, artificial intelligence can be applied to optimize detection standards, and large-sample clinical trials should be carried out to further explore the clinical potential of TILs.

Downloads

Download data is not yet available.

References

[1] Kashyap D, Pal D, Sharma R, et al. Global increase in breast cancer incidence: risk factors and preventive measures. BioMed Research International, 2022, 2022: 685–688. DOI: https://doi.org/10.1155/2022/9605439

[2] Navrátil J, Fabian P, Palácová M, et al. Triple negative breast cancer. Klin Onkologie, 2015, 28(6): 406–415. DOI: https://doi.org/10.14735/amko2015405

[3] Thomas A, Reis-Filho JS, Geyer CE Jr, Wen HY. Rare subtypes of triple negative breast cancer: current understanding and future directions. npj Breast Cancer, 2023, 9(1): 55. DOI: https://doi.org/10.1038/s41523-023-00554-x

[4] Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. Journal of Clinical Oncology, 2021, 39(13): 1485–1505. DOI: https://doi.org/10.1200/JCO.20.03399

[5] van den Ende NS, Nguyen AH, Jager A, et al. Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review. International Journal of Molecular Sciences, 2023, 24(3): 2969. DOI: https://doi.org/10.3390/ijms24032969

[6] Zhao Y, Jiang SJ, Wang JL, et al. Correlation study of tumor-infiltrating lymphocytes (TILs) and subtypes analysis before and after neoadjuvant chemotherapy in triple-negative breast cancer. Gland Surgery, 2025, 14(4): 628–645. DOI: https://doi.org/10.21037/gs-2024-537

[7] Virassamy B, Salgado R, Loi S. Clinical validity and utility of tumor-infiltrating lymphocytes in routine clinical practice for breast cancer patients: current and future directions. Frontiers in Oncology, 2017, 7: 156. DOI: https://doi.org/10.3389/fonc.2017.00156

[8] Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Molecular Cancer, 2021, 20: 131. DOI: https://doi.org/10.1186/s12943-021-01428-1

[9] Zhou Y, Tian Q, Wang BY, et al. The prognostic significance of TILs as a biomarker in triple-negative breast cancer. European Review for Medical and Pharmacological Sciences, 2021, 25(7): 2885–2897.

[10] Han JW, Su TT, Xu YB, Hu CH. Research progress of tumor infiltrating lymphocytes in predicting the efficacy of neoadjuvant chemotherapy for triple negative breast cancer. Chinese Journal of Clinical Oncology, 2023, 50(19): 1011–1016.

[11] Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cellular and Molecular Immunology, 2021, 18(4): 842–859. DOI: https://doi.org/10.1038/s41423-020-00565-9

[12] Xu X, Yi C, Feng T, et al. Regulating tumor microenvironments by a lymph node-targeting adjuvant via tumor-specific CTL-derived IFNγ. Clinical Immunology, 2023, 253: 109685. DOI: https://doi.org/10.1016/j.clim.2023.109685

[13] Ahmadvand S, Faghih Z, Montazer M, et al. Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients. Cellular Oncology, 2019, 42(3): 343–356. DOI: https://doi.org/10.1007/s13402-019-00430-6

[14] Hong S, et al. B cells are the dominant antigen-presenting cells that activate naive CD4+ T cells upon immunization with a virus-derived nanoparticle antigen. Immunity, 2018, 49: 695–708.e4. DOI: https://doi.org/10.1016/j.immuni.2018.08.012

[15] Kroeger DR, Milne K, Nelson BH. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clinical Cancer Research, 2016, 22: 3005–3015. DOI: https://doi.org/10.1158/1078-0432.CCR-15-2762

[16] Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. Journal of Clinical Oncology, 2010, 28: 105–113. DOI: https://doi.org/10.1200/JCO.2009.23.7370

[17] Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. Journal of Clinical Oncology, 2019, 37(7): 559–569. DOI: https://doi.org/10.1200/JCO.18.01010

[18] Geurts VCM, Balduzzi S, Steenbruggen TG, et al. Tumor-infiltrating lymphocytes in patients with stage I triple-negative breast cancer untreated with chemotherapy. JAMA Oncology, 2024, 10(8): 1077–1086. DOI: https://doi.org/10.1001/jamaoncol.2024.1917

Downloads

Published

15-11-2026

Issue

Section

Articles

How to Cite

Xu, Y. (2026). Predictive Value of Tumor-Infiltrating Lymphocytes for Neoadjuvant Chemotherapy Among Triple-Negative Breast Cancer. International Journal of Biology and Life Sciences, 17(2), 32-36. https://doi.org/10.54097/j931ky70